In The News

Ropes & Gray Represents EQRx in Turning Point Therapeutics Collaboration on Combination Drug for Non-Small Cell Lung Cancer

Practices: Life Sciences, Health Care, Mergers & Acquisitions, Health Care Finance & Restructuring, Life Sciences Licensing, Collaborations & Joint Ventures, Biomedical Research: Human, Animal and Bench Science

Ropes & Gray advised EQRx in a clinical collaboration with oncology company Turning Point Therapeutics to evaluate Turning Point’s drug elzovantinib and EQRx’s drug aumolertinib for a certain type of advanced non-small cell lung cancer. The transaction was announced on October 13.

Under the terms of the agreement, Turning Point will sponsor and conduct a Phase 1b/2 clinical trial expected to begin in 2022 to evaluate the safety, tolerability and preliminary efficacy of the combination regimen.

The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate Amanda White (both of Boston).

Cookie Settings